Long-Term Efficacy and Safety of Risankizumab for csDMARD-IR Patients With Active Psoriatic Arthritis: 196-Week Results From the KEEPsAKE 1 Trial. J of Skin. 2024;8(6):s445. doi:10.25251/skin.8.supp.445